ARC-20: A phase 1 dose-escalation and dose-expansion study to investigate the safety, tolerability, and pharmacology of HIF-2α inhibitor AB521 monotherapy in patients with clear cell renal cell carcinoma and other solid tumors.

Authors

Toni K. Choueiri

Dana Farber Cancer Institute and Harvard Medical School, Boston, MA

Toni K. Choueiri , Benjamin Garmezy , Elaine Paterson , Mohammad Ghasemi , Tzuling Cheng , Paul G. Foster , Ralph J. Hauke , Amita Patnaik

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.

First Author: J. Thaddeus Thaddeus Beck

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.

First Author: Gary Edward Richardson

insert_chart_outlined

Poster

2019 Genitourinary Cancers Symposium

bookmark_border

Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.

First Author: Brian I. Rini

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Results of a phase I study of RX-5902: An orally bioavailable inhibitor of phosphorylated P68, targeting solid tumors.

First Author: S. Gail Eckhardt